Business Description
IRLAB Therapeutics AB
ISIN : SE0012675361
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.65 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -1.38 | |||||
Beneish M-Score | 2.64 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -21.3 | |||||
3-Year EPS without NRI Growth Rate | -21.3 | |||||
3-Year FCF Growth Rate | -19.2 | |||||
3-Year Book Growth Rate | -32.2 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 67.63 | |||||
9-Day RSI | 64.24 | |||||
14-Day RSI | 59.82 | |||||
6-1 Month Momentum % | 72.08 | |||||
12-1 Month Momentum % | 21.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.45 | |||||
Quick Ratio | 2.45 | |||||
Cash Ratio | 2.13 | |||||
Days Sales Outstanding | 983.05 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -1.29 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2798.43 | |||||
Net Margin % | -2770.38 | |||||
FCF Margin % | -2911 | |||||
ROE % | -103.74 | |||||
ROA % | -78.02 | |||||
ROIC % | -175.19 | |||||
ROC (Joel Greenblatt) % | -2532.97 | |||||
ROCE % | -95.83 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 144.5 | |||||
PB Ratio | 10.66 | |||||
Price-to-Tangible-Book | 26.6 | |||||
EV-to-EBIT | -4.97 | |||||
EV-to-EBITDA | -5.12 | |||||
EV-to-Forward-EBITDA | -5.04 | |||||
EV-to-Revenue | 135.86 | |||||
EV-to-Forward-Revenue | 23.66 | |||||
EV-to-FCF | -4.77 | |||||
Price-to-Net-Current-Asset-Value | 33.25 | |||||
Price-to-Net-Cash | 66.5 | |||||
Earnings Yield (Greenblatt) % | -20.12 | |||||
FCF Yield % | -19.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
IRLAB Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.482 | ||
EPS (TTM) (€) | -0.265 | ||
Beta | 0.52 | ||
Volatility % | 98.07 | ||
14-Day RSI | 59.82 | ||
14-Day ATR (€) | 0.056816 | ||
20-Day SMA (€) | 1.12365 | ||
12-1 Month Momentum % | 21.75 | ||
52-Week Range (€) | 0.52 - 1.715 | ||
Shares Outstanding (Mil) | 51.87 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
IRLAB Therapeutics AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
IRLAB Therapeutics AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
IRLAB Therapeutics AB Frequently Asked Questions
What is IRLAB Therapeutics AB(FRA:6IRA)'s stock price today?
When is next earnings date of IRLAB Therapeutics AB(FRA:6IRA)?
Does IRLAB Therapeutics AB(FRA:6IRA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |